Association Between Blood Type and Epidermal Growth Factor Receptor Mutation Positivity in Lung Adenocarcinoma Patients
Received Date : 16 Nov 2020
Accepted Date : 30 Dec 2020
Available Online : 02 Feb 2021
Doi: 10.37047/jos.2020-79248 - Article's Language: EN
J Oncol Sci. 2021;7(1):20-4
This is an open access article under the CC BY-NC-ND license
Objective: Specific ABO blood group and Rh antigens are found to be associated with several malignancies and lung cancer. However, the relationship between blood type and Epidermal Growth Factor Receptor (EGFR) mutation in lung cancer remains poorly investigated. Material and Methods: In this retrospective case-control study, 105 EGFR mutation-positive and 169 EGFR mutation-negative lung adenocarcinoma patients were included. Baseline characteristics of the patients were determined. Odds ratios were calculated for the relationship of EGFR mutation positivity according to the ABO and Rh blood type. Overall survival difference according to the blood types was analyzed in metastatic patients that were diagnosed in the EGFR-mutant group. Results: There was no statistically significant increase observed in the relationship of EGFR mutation positivity for any of ABO and Rh types (OR and p-value, respectively; A: 1.15–0.57, B: 0.68– 0.28, AB: 1–0.98, O: 1.06–0.82, Rh: 1.04–0.91). There was no statistically significant overall survival difference between ABO types (16, 21.1, 18.9, 24.9 months for O, A, B, AB blood groups, respectively). Conclusion: No significant association between blood type and EGFR mutation positivity in lung adenocarcinoma could be established.
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. [Crossref]  [PubMed] 
  2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. [Based on November 2018 SEER data submission, posted to the SEER web site, April 2019]. Bethesda, MD: National Cancer Institute 2019.
  3. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285. [Crossref]  [PubMed]  [PMC] 
  4. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 2014;311:1998-2006. [Crossref]  [PubMed]  [PMC] 
  5. Doval DC, Desai CJ, Sahoo TP. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. Indian J Cancer. 2019;56:S23-s30. [Crossref]  [PubMed] 
  6. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865. [Crossref]  [PubMed] 
  7. Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology. 2014;9:154-162. [Crossref]  [PubMed]  [PMC] 
  8. Musayeva M, Sak SD, Ozakinci H, Boyacıgil Ş, Coşkun Ö. Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center. Turk Gogus Kalp Damar Cerrahisi Derg. 2020;28:143-150. [Crossref]  [PubMed]  [PMC] 
  9. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer research. 2004;64:8919-8923. [Crossref]  [PubMed] 
  10. Hosoi E. Biological and clinical aspects of ABO blood group system. The journal of medical investigation. 2008;55:174-182. [Crossref]  [PubMed] 
  11. Vasan SK, Hwang J, Rostgaard K, et al. ABO blood group and risk of cancer: A register-based cohort study of 1.6 million blood donors. Cancer epidemiology. 2016;44:40-43. [Crossref]  [PubMed] 
  12. Chrysanthakopoulos N, Dareioti N. ABO blood group and the risk of lung cancer in Greek adults: a case-control study. Experimental oncology 2018. [Crossref] 
  13. Hsiao LT, Liu NJ, You SL, Hwang LC. ABO blood group and the risk of cancer among middle‐aged people in T aiwan. Asia‐Pacific Journal of Clinical Oncology. 2015;11:e31-e36. [Crossref]  [PubMed] 
  14. Li N, Xu M, Li CF, et al. Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center. Chin J Cancer. 2015;34:475-482. [Crossref]  [PubMed]  [PMC] 
  15. Urun Y, Utkan G, Cangir AK, et al. Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey. Asian Pac J Cancer Prev. 2013;14:2801-2803. [Crossref]  [PubMed] 
  16. Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clin Cancer Res. 1997;3:87-93.
  17. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med. 1991;324:1084-1090. [Crossref]  [PubMed] 
  18. Fukumoto K, Taniguchi T, Usami N, et al. The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer. J Epidemiol. 2015;25:110-116. [Crossref]  [PubMed]  [PMC] 
  19. Unal D, Eroglu C, Kurtul N, Oguz A, Taşdemir A, Kaplan B. ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:3945-3948. [Crossref] 
  20. Oguz A, Unal D, Tasdemir A, et al. Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev. 2013;14:453-456. [Crossref]  [PubMed] 
  21. Zhou J, Mo W, Zhao J, Zheng J, Ding W, Zhou J. Clinicopathological features associated with EGFR gene mutation in non-small cell lung cancer patients. Zhonghua yi xue za zhi. 2014;94:2332-2336.
  22. Wang CD, Wang XR, Wang CY, Tang YJ, Hao MW. Relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma. Asian Pac J Trop Med. 2015;8:249-252. [Crossref] 
  23. Hejna M, Birner P, Preusser M, et al. Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. Mol Clin Oncol. 2013; 1:1079-1083. [Crossref]  [PubMed]  [PMC] 
  24. Urun Y, Utkan G, Altundag K, et al. ABO and Rh blood groups frequency in women with HER2 positive breast cancer. J buon. 2012; 17:457-460.
  25. Klimant E, Glurich I, Mukesh B, Onitilo AA. Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort. Clin Med Res. 2011;9 :111-118. [Crossref]  [PubMed]  [PMC]